NIP
TLIS

Nicholas Investment Partners’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

Nicholas Investment Partners’s Portfolio TLIS Stock Details TLIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-65,939
Closed -$6.18M – 214
2021
Q3 		$6.18M Sell
65,939
-5,482
-8% -$730K 0.45% 83
2021
Q2 		$11.8M Sell
71,421
-2,006
-3% -$341K 0.74% 49
2021
Q1 		$14.2M Buy
+73,427
New +$18.3M 0.99% 42

Other funds holding TLIS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Nicholas Investment Partners's TLIS Position: Q4 2021 in Review

Nicholas Investment Partners sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q4 2021, closing a stake of 65,939 shares — an estimated $6.18M sold.

Nicholas Investment Partners first reported a position in TLIS in Q1 2021 and held it in 3 quarters. The position peaked at $14.2M in Q1 2021. 46 funds tracked by Wall St. Rank hold TLIS as of Q4 2021.

  • Nicholas Investment Partners reported no remaining Talis Biomedical Corporation Common Stock position as of Q4 2021 after selling out during the quarter.
  • Nicholas Investment Partners sold 65,939 Talis Biomedical Corporation Common Stock shares in Q4 2021, an estimated $6.18M.
  • Nicholas Investment Partners first reported a position in Talis Biomedical Corporation Common Stock in Q1 2021 and held it in 3 quarters.
  • Nicholas Investment Partners's Talis Biomedical Corporation Common Stock position peaked at $14.2M in Q1 2021.
  • 46 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q4 2021.

Based on Nicholas Investment Partners's 13F filing for Q4 2021, filed 14 Feb 2022.